the standard advice is hold each dose 4 weeks before stepping up, and most people treat that as a hard rule. it isn’t, it’s a trial protocol artifact that got translated into clinical practice because it was the cadence the SURMOUNT trials used. the underlying PK actually argues for something a little more textured. tirz half-life is ~5 days, so steady state on a given dose lands around day 20-25. that’s where the 4-week thing comes from, you want to titrate from a stable baseline, not a still-climbing one. fine. but GI tolerance and PK steady state are not the same clock. tachyphylaxis at the receptor, particularly the GIP arm, kicks in faster than steady state in a lot of people. so the question of “am i tolerating this dose” is often answerable at 2-3 weeks, even if the trough is still drifting up. where this matters: people sitting on 5mg for 8 weeks because they’re scared to move, when the GI symptoms resolved at week 2 and the appetite suppression has plateaued. that’s a different problem than someone who’s still nauseous at week 4. fwiw i log dose, injection day, and a 1-5 nausea score in the careclinic check-in, takes maybe fifteen seconds and the pattern shows up faster than you’d think. half-life on paper, vibes in practice; you need both to titrate sensibly. not dosing advice, just the PK frame i wish someone had handed me earlier.
‘am i tolerating this dose’ is answerable early, but ime the answer’s often wrong. my sulfur burps cleared at week 2 and i genuinely thought it was a go signal, but appetite suppression was still shifting at week 5. dosing up early would have been premature. resolving GI symptoms doesn’t mean teh medication is done working yet.
Pulling the GI tolerance clock apart from PK steady state is genuinely useful framing. Where I’d push back: “appetite suppression has plateaued” at week 2-3 isn’t the same signal as metabolic effect having settled. Fasting insulin and glucose response can still be drifting at that point even when nausea is resolved. For anyone on tirz specifically for insulin resistance, those are the numbers that actually tell you whether a dose is doing work, and they don’t reliably track with appetite on the same timeline.
sulfur burps clearing is a GI-tract adaptation clock, not a central appetite clock, and you’re right that conflating them is the trap. the receptor desensitization story i was gesturing at is mostly the GIP arm and mostly peripheral; the GLP-1 driven satiety signal keeps shifting for weeks after the gut has stopped complaining. so “tolerating” answers early, “working” answers late, and they’re genuinely different questions on different timelines. the people who get burned are usually the ones who collapsed those two into one.
the PK frame holds, and the 4-week trial cadence really did get translated into clinical bedrock without much examination, that part i’m with you on. where i’d add a caveat: “appetite suppression has plateaued” is doing some work that the receptor-level argument doesn’t quite license. subjective satiety plateau and the metabolic endpoints (fasting glucose, fasting insulin, post-prandial excursions) don’t read on the same clock, and the lab-response curve to a given dose is genuinely slower than the GI tolerance curve in my own logs. so for someone titrating primarily for weight, the 2-3 week tolerability read is probably enough to justify a step-up. for someone titrating because their A1c was 6.1 and they want to see what 5mg actually does to their fasting numbers before deciding 7.5 is necessary, the 4-week hold is doing different work, you’re not waiting for steady state in the trough, you’re waiting for the downstream metabolic adaptations to actually show up in a fasting draw. i sat on 5mg longer than the protocol suggested for that reason, fasting glucose kept drifting down through what would have been week 4-5 on an unchanged dose, and that movement would have been invisible if i’d stepped up at week 3 on GI tolerance alone. the GIP tachyphylaxis piece is also one i’d want to be careful with. the receptor-desensitization literature on GIP-R in humans (vs cell lines) is thinner than the framing usually suggests, probably directionally right, but the kinetics aren’t well-characterized enough to lean on for a “tolerance plateaued at week 2 therefore step up” read in any individual. fine as a hypothesis, less fine as a clock.
the “GI tolerance and PK steady state are not the same clock” framing is the part most guides skip entirely, and it matters a lot for T2D specifically bc appetite suppression isn’t the primary therapeutic event at 2.5mg anyway. for people on tirz for glycemic control, sitting an extra month at a subtherapeutic dose has a real cost that the “go slow to be safe” frame doesn’t account for. my CGM 14-day average was still drifting at week 3 on 5mg but GI symptoms had resolved by day 18, and that distinction was exactly what my endo used to justify stepping up on schedule rather than waiting the full 8 weeks some people stretch it to. the nausea score log is genuinely useful for that conversation, pattern data beats self-report from memory every time
the PK frame is solid and the trial-cadence-as-bedrock point is one I’d echo without hesitation, but “appetite suppression has plateaued” is the phrase I’d sit with a bit longer before resting weight on it. that’s subjective satiety, and subjective satiety plateauing is not the same finding as metabolic endpoint plateauing on the same dose. those are different curves with different integration windows, and the receptor-level story you’re invoking to license stepping up earlier is actually a story about the second one, not the first. in practice they often track, sure, but they don’t have to, and the people i’ve seen get this wrong are the ones who felt their hunger come back at week 3 and read that as “the dose stopped working” when their fasting glucose was still trending in the right direction. those are two different questions about the same molecule and i’d want to keep them separated before licensing a dose move off the subjective signal alone. the tachyphylaxis-on-the-GIP-arm bit is the other one i’d want to slow down on. the receptor desensitization literature on GIP is genuinely interesting but it’s also thinner and more in vitro than the way it gets cited in patient communities, and the leap from “GIP receptor internalizes faster than GLP-1R in cell culture” to “your nausea resolved because tachyphylaxis kicked in at week 2” is a fair distance. the GI symptoms resolving at week 2 has a perfectly mundane gastric emptying adaptation story attached to it that doesn’t require the receptor argument at all. directionally i think you’re right that GI tolerance and PK steady state run on different clocks, that part i’m with you on, but i’d be careful about which mechanism you’re crediting for which observation, because the receptor frame is being asked to do more work than the data has really licensed yet.